Boehringer Buoyed By Progress Of Oncology Pipeline
Brigimadlin Moves Into Pivotal Trials
Boehringer Ingelheim is enjoying the financial benefits that have come from the strong growth of Jardiance and has upped its R&D spend to advance promising cancer and fibrosis assets.
